Antipsychotic agents and sudden cardiac death - How should we manage the risk?

New England Journal of Medicine

Volumn 360, Issue 3, 2009, Pages 294-296

  Schneeweiss, Sebastian ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

AGRANULOCYTOSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESEARCH; EDITORIAL; HEART DEATH; HUMAN; MEDICAL ASSESSMENT; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SUDDEN DEATH;

EID: 58349114440     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0809417     Document Type: Editorial

References (16)

1. Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin 2007;23:49-56.
2. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005;165:1280-5.
3. IMS Health. Top ten global products. 2007. (Accessed December 22, 2008, at http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/Top10GlobalProducts.pdf.)
4. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
5. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
6. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
7. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47:731-7. [Erratum, J Clin Epidemiol 2004;57:111.]
8. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992;327:168-73.
9. Paling J. Strategies to help patients understand risks. BMJ 2003;327:745-8.
10. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
12. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
13. Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000;61:344-8.
14. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
15. Kelly DL, Dixon LB, Kreyenbuhl JA, et al. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry 2006;67:1404-11.
16. Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J. Should clozapine continue to be restricted to third-line status for schizophrenia? A decision-analytic model. J Ment Health Policy Econ 2004;7:77-85.